Pieris Pharmaceuticals Inc (PIRS) : Omega Fund Management reduced its stake in Pieris Pharmaceuticals Inc by 8.9% during the most recent quarter end. The investment management company now holds a total of 2,262,832 shares of Pieris Pharmaceuticals Inc which is valued at $3,914,699 after selling 221,117 shares in Pieris Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 3, 2016.Pieris Pharmaceuticals Inc makes up approximately 2.90% of Omega Fund Management’s portfolio.
Other Hedge Funds, Including ,
Pieris Pharmaceuticals Inc closed down -0.02 points or -1.19% at $1.66 with 1,36,533 shares getting traded on Monday. Post opening the session at $1.68, the shares hit an intraday low of $1.65 and an intraday high of $1.7438 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Pieris Pharmaceuticals Inc. Pieris Pharmaceuticals Inc was Resumed by ROTH Capital to “Buy” on Aug 5, 2016.
Pieris Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of Anticalin class of biotherapeutics for patients with diseases. The Company is focused on developing two drug candidates PRS-080 and PRS-060. PRS-080 is an Anticalin protein that binds to hepcidin a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency (FID) in anemic patients with chronic kidney disease (CKD) in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor thereby inhibiting IL-4 and IL-13 two cytokines small proteins mediating signaling between cells within the human body which are mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. It is also developing PRS-110 in cMet-related cancer and PRS-300 series.